1. Leonard S. Schleifer, M.D., Ph.D. - Board Co-Chair, President and Chief Executive Officer (Principal Executive Officer).
2. George D. Yancopoulos, M.D., Ph.D. - Board Co-Chair, President and Chief Scientific Officer.
3. Robert E. Landry - Executive Vice President, Finance and Chief Financial Officer (Principal Financial Officer).
4. Christopher Fenimore - Senior Vice President, Controller (Principal Accounting Officer).
5. Craig B. Thompson - Director.
6. Bonnie L. Bassler - Director.
7. Kathryn Guarini - Director.
8. Christine A. Poon - Director.
9. George L. Sing - Director.
10. Michael S. Brown - Director.
11. Arthur F. Ryan - Director.
12. David P. Schenkein - Director.
13. Huda Y. Zoghbi - Director.
14. Joseph L. Goldstein, M.D. - Director.
15. N. Anthony Coles - Director.,
Regeneron Pharmaceuticals Inc currently has 15410 employees.
News about Regeneron Pharmaceuticals Inc Key Personnel |
In recent groundbreaking news, the European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of odronextamab for the treatment of relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). This recommendation comes after extensive analysis of the Phase 1 and pivotal Phase 2 clinical trials, which showcased remarkable response rates and durable outcomes for patients with these challenging malignancies.
The recommendation is based on compelling evidence from the trials, demonstrating the robust and durable response rates of odronextamab in patients with relapsed/refractory FL and DLBCL. These lymphomas are known to ...
|
Regeneron Faces Regulatory Hurdles for Odronextamab, Potential Treatment for Lymphomas
TARRYTOWN, N.Y., March 25, 2024 - Pharmaceutical company Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has provided an update on its Biologics License Application (BLA) for odronextamab, a potential treatment for relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL). The U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) regarding the application, citing the enrollment status of the confirmatory trials as the only issue. However, the CRLs did not raise any concerns regarding the drug s clinical efficacy, safety, trial design, labeling, or manu...
|
